EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy

Augusto B Federici iD, Rita Carlotta Santoro, Cristina Santoro, Lisa Pieri, Roberto Mario Santi, Giovanni Barillari, Alessandra Borchiellini, Alberto Tosetto, Ezio Zanon, Raimondo De Cristofaro, Esther Mairal, Roser Mir

Clinical and Applied Thrombosis/Hemostasis · 2024

DOI: 10.1177/10760296241264541 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2024. Verfasst von Augusto B Federici und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology and Haemotherapy, Luigi Sacco Hospital, Milano, Italy. Hauptthemen laut MEDLINE: von Willebrand Diseases, von Willebrand Factor, Factor VIII. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grifols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma-derived von Willebrand factor-containing factor VIII concentrates (pd-VWF/FVIII-C) are the mainstay of treatment in von Willebrand disease (VWD). Real-world data on efficacy and safety of these pd-VWF/FVIII-C are required. To retrospectively evaluate the efficacy and safety of pd-VWF/FVIII-C (Fanhdi® and Alphanate®, Grifols) in clinical practice in Italy. A multicentric, observational, retrospective study at 10 Italian centers was conducted. Eligible patients diagnosed with inherited VWD (ISTH criteria) were treated with either Fanhdi® or Alphanate® for bleeding episodes, prevention of surgical bleeding and secondary long-term prophylaxis (SLTP) according to clinical practice with medical records collected from January 2007 to December 2019. Efficacy/safety of pd-VWF/FVIII-C was assessed according to FDA-agreed objective criteria following regulatory procedures. Fifty-seven patients (M/F: 21/36) were enrolled in the study with the following VWD types: VWD1 (n = 29, 52%), VWD2A (n = 10, 18%), VWD2B (n = 7, 12%), VWD2M (n = 2, 4%), VWD2N (n = 1, 2%), VWD2 unclassified (n = 1, 2%), and VWD3 (n = 7, 12%). These pd-VWF/FVIII-C were used to manage 58 bleeding episodes (n = 24 patients), 100 surgeries (n = 47 patients), and 7 SLTP (n = 6 patients). Global clinical efficacy with these pd-VWF/FVIII-C was reported to be excellent/good in 85% of bleeding episodes, 98% of surgeries, and 100% of SLTP. As far as safety, no adverse-drug-related episodes, immunogenic or thrombotic events were reported. This study confirmed that Fanhdi® and Alphanate® were effective and safe in the management of bleeding episodes, the prevention of bleeding during surgeries and for SLTP in Italian patients with inherited VWD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Diseasesvon Willebrand FactorFactor VIIIHumansItalyMaleFemaleRetrospective StudiesAdultMiddle AgedAdolescentYoung AdultChildAgedChild, Preschool

Stichwörter der Autor:innen

bleedingplasma-derived von Willebrand factor / factor VIII concentratesecondary long-term prophylaxissurgeryvon Willebrand disease

Substanzen

von Willebrand FactorFactor VIII

Autor:innen und Institutionen

  • Department of Haematology and Haemotherapy, Luigi Sacco Hospital, Milano, Italy.
  • Haemophilia Centre, Haemostasis and Thrombosis Unit, Department of Haemato-Oncology, Azienda Ospedaliero-Universitaria Dulbecco, Catanzaro, Italy.
  • Department of Hematology, University Hospital Policlinico Umberto I, Rome, Italy.
  • Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.
  • SSD Thrombosis and Hemostasis Center, Azienda Ospedaliera "SS Antonio e Biagio e C. Arrigo", Alessandria, Italy.
  • Center for Hemorrhagic and Thrombotic Diseases, Udine General and University Hospital "S. Maria della Misericordia", Udine, Italy.

ORCID-Profile: Augusto B Federici

Förderung

  • Grifols

Zitieren

APA

Federici, A. B., Santoro, R. C., Santoro, C., Pieri, L., Santi, R. M., Barillari, G., Borchiellini, A., Tosetto, A., Zanon, E., De Cristofaro, R., Mairal, E., & Mir, R. (2024). Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296241264541

Vancouver

Federici AB, Santoro RC, Santoro C, Pieri L, Santi RM, Barillari G, et al. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy. Clinical and Applied Thrombosis/Hemostasis. 2024. doi:10.1177/10760296241264541

BibTeX
@article{Federici2024,
  author = {Federici, Augusto B and Santoro, Rita Carlotta and Santoro, Cristina and Pieri, Lisa and Santi, Roberto Mario and Barillari, Giovanni and Borchiellini, Alessandra and Tosetto, Alberto and Zanon, Ezio and De Cristofaro, Raimondo and Mairal, Esther and Mir, Roser},
  title = {Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2024},
  doi = {10.1177/10760296241264541}
}
Kostenlos starten →